Interactive chart of Johnson & Johnson (JNJ) annual worldwide employee count from 2010 to 2023.
See Also
About Us | TDK China| Johnson & Johnson Annual Employee Count | |
|---|---|
| 2023 | 131,900 |
| 2022 | 155,800 |
| 2021 | 141,700 |
| 2020 | 134,500 |
| 2019 | 132,200 |
| 2018 | 135,100 |
| 2017 | 134,000 |
| 2016 | 126,400 |
| 2015 | 127,100 |
| 2014 | 126,500 |
| 2013 | 128,100 |
| 2012 | 127,600 |
| 2011 | 117,900 |
| 2010 | 114,000 |
| 2009 | 115,500 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $380.216B | $85.159B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $722.648B | 120.34 |
| Novo Nordisk (NVO) | Denmark | $572.385B | 47.15 |
| Merck (MRK) | United States | $331.751B | 87.33 |
| AbbVie (ABBV) | United States | $320.062B | 16.27 |
| AstraZeneca (AZN) | United Kingdom | $208.503B | 18.48 |
| Novartis AG (NVS) | Switzerland | $203.206B | 14.08 |
| Pfizer (PFE) | United States | $156.966B | 15.15 |
| Sanofi (SNY) | $122.155B | 11.00 | |
| Innoviva (INVA) | United States | $0.962B | 6.79 |
